Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Lenvima (lenvatinib by Year
Lenvima (lenvatinib — Eisai oncology alliance revenue) — Worldwide sales ($M) ($M)
Merck Lenvima (lenvatinib: $1,053M in FY2025, up 4.3% from a year earlier. That is the highest of the 10 years on record here.
Where the FY2025 figure comes from
“|| Alliance Revenue – Lenvima (2) | 256 | 283 | 539 | 258 | 265 | 523 | 258 | 272 | 1,053 | 7 | 6 | 3 | 2”
Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lenvima (lenvatinib — Eisai oncology alliance revenue) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,053 | +4.3% | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| FY2024 | Dec 31, 2024 | 1,010 | +5.2% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 960 | +9.6% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 876 | +24.4% | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 704 | +21.4% | Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗ |
| FY2020 | Dec 31, 2020 | 580 | +43.6% | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2019 | Dec 31, 2019 | 404 | +171.1% | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
| FY2018 | Dec 31, 2018 | 149 | – | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2017 | Dec 31, 2017 | 0 | – | Form 10-K (filed 2020-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 0 | – | Form 10-K (filed 2019-02-27) ↗ |
Breakdown
What makes up lenvima (lenvatinib
- Lenvima (lenvatinib — Eisai oncology alliance revenue) — U.S. sales ($M)737 · FY2025
- Lenvima (lenvatinib — Eisai oncology alliance revenue) — International sales ($M)316 · FY2025
- Lenvima (lenvatinib — Eisai oncology alliance revenue) — Worldwide reported growth YoY (%)4.0% · FY2025
- Lenvima (lenvatinib — Eisai oncology alliance revenue) — Worldwide constant-currency (ex-exchange) growth YoY (%)4.0% · FY2025
Cite this data
StockData. (2026). Merck Lenvima (lenvatinib ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-lenvima
See every metric in the Merck KPI table. Data updated Oct 26, 2026.